This site is intended for healthcare professionals

Keytruda is now approved for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) mutations/megabase] solid tumors.- Merck inc.

Read time: 3 mins
Last updated:19th Jun 2020
Published:18th Jun 2020
Condition: Solid Tumours/Tumour Mutational Burden
Type: drug
Register free for full access to